Eric Dane, who is known for his iconic roles as Dr. Mark Sloan in Grey’s Anatomy and Cal Jacobs in HBO’s hit drama Euphoria, has been a familiar face in Hollywood for over two decades. Known for his charisma on screen and commanding performances, the 52-year-old actor recently made headlines not for a new project, but for a deeply personal health revelation.
Dane, in an interview with People magazine exclusively, had said that he had been diagnosed with ALS (amyotrophic lateral sclerosis), a progressively developing and presently incurable neurodegenerative illness. But even amidst the diagnosis, he is cheerful, continuing to work and counting on the assistance of his family for this new chapter in life.
Amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, is a rare but tragic neurological disorder that slowly takes away people's motor skills, speech, swallowing, and finally, breathing. Although the name sounds technical-sounding, it tells what the disease does—no muscle nourishment and muscle weakness and paralysis. The term also addresses the spine, in which nerve injury begins, and the scarring that develops over a period of time. As more individuals become informed, especially following publicized diagnoses like that of actor Eric Dane, discovering the etiology and facts about ALS becomes more valuable.
During an interview with a leading media outlet, the 52-year-old actor disclosed, "I feel so lucky that I'm still employed and can't wait to be returning to the Euphoria set next week." The actor was appreciative of the love and support of his family members, requesting that they be given some privacy while they "move forward in this next chapter."
As shocking as this announcement will be to followers everywhere, it's also a wake-up call for awareness: what is ALS, what are the symptoms in its onset, who is at risk, and what are the hurdles ahead for those afflicted? Eric Dane's public revelation places ALS in the global spotlight, evoking not just sympathy, but education and activism. His own experience will undoubtedly increase awareness and advocacy for a disease all too often endured in silence.
ALS, also known as Lou Gehrig's disease, is the most common form of motor neuron disease (MND). The illness causes the progressive breakdown and death of motor neurons—nerve cells that manage voluntary muscle movement, including walking, talking, swallowing, and breathing.
The title "amyotrophic lateral sclerosis" comes from Greek, each word describing the nature of the disease. "A" means "no," "myo" means "muscle," and "trophic" connotes "nourishment," all of which combined mean "no muscle nourishment"—a name that succinctly describes the muscle wasting, or atrophy, of the disease. "Lateral" indicates the specific regions of the spinal cord that are affected, and "sclerosis" denotes the scarring or hardening that takes place in these regions as the disease progresses.
Symptoms of ALS can start subtly but rapidly progress, so early detection is important. The disease tends to begin with localized weakness or muscle twitching, typically in the hands, legs, or speech muscles.
Early symptoms, according to the Mayo Clinic, are:
These symptoms become more severe over time and spread to other areas of the body. Ultimately, people lose the capacity to move, talk, eat, and breathe on their own.
ALS progresses in an relentless degenerative way. When motor neurons die, they weaken and shrink the muscles that they serve. Initially, a person may experience everyday tasks as a hassle, but eventually, in months or years, these issues may progress to full paralysis.
Despite the preservation of a normal mentality, certain people do experience cognitive or behavioral changes, and some proportion may have frontotemporal dementia.
The life expectancy is three to five years after the diagnosis, yet some patients are able to survive a decade or more with it.
Although there is much left to be discovered about ALS, there are numerous factors that predispose individuals toward developing the disorder:
Around 10% of all ALS diagnoses are inherited. Individuals with a family history of ALS have significantly higher risk, and their children have a 50% chance of inheriting the gene mutation.
ALS typically strikes those between the ages of 60 and 75. Men are slightly more likely to develop the disease than women before age 65, but this gender disparity evened out with advancing age.
Studies have linked some exposures to increased ALS risk:
Smoking: Particularly in women after menopause.
Toxic exposures: e.g., lead or industrial toxins.
Military service: Statistically, veterans are more likely to develop ALS, perhaps due to severe physical stress, toxin exposure, or infections.
As ALS advances, it doesn't just affect movement—it affects nearly every function that depends on muscle control. Some serious complications include:
Respiratory Failure: Weakening of the diaphragm and chest muscles creates breathlessness. Most patients require ventilatory support, and respiratory failure is the main cause of death in ALS.
Speech and Communication Deficit: The disease will lead to slurred speech or mumbling so that there is dependence on aids to communication.
Difficulty Swallowing and Feeding: Weakening of the muscles disrupts chewing and swallowing capacity so that patients become vulnerable to aspiration pneumonia or choking. Feeding tubes are most often required.
Dementia and Cognitive Impairment: A small percentage of ALS patients develop frontotemporal dementia, which is marked by changes in behavior and decision-making.
In spite of the gravity of the diagnosis, Eric Dane has been said to have been upbeat and to have promised to keep working. This is typical of the resilience that many with ALS exhibit. With supportive care, assistive technology, and improvement in symptomatic treatment, individuals can maintain quality of life for as long a time as possible.
However, the fact that there is no cure also highlights the utter need for more research, funding, and activism. Organizations like the ALS Association and the Muscular Dystrophy Association are strongly advocating improved treatments as well as maybe even breakthroughs.
Credits: Canva
The UKHSA has noted that a new strain of COVID-19 virus, called Stratus, with two variants, XFG and XFG.3, has accounted for a high proportion cases in England, reports the Independent. Among these two variants, XFG.3 has accounted for 30% of cases in the country.
However, experts have suggested to not panic on the arrival of this new strain. Dr Alex Allen, consultant epidemiologist of UKHSA said, "It is normal for viruses to mutate and change over time," as reported by the Independent. However, the UKHSA has also confirmed that it continues to monitor all strains of COVID in the UK. For now, experts are not concerned over the spread.
As per the World Health Organization (WHO), XFG is a "variant under monitoring" and that any health risk posed by this variant remain low at the global level.
As of now, globally, XFG has the highest relative growth when compared to the other variants that are currently active and circulating, including "Nimbus" NB.1.8.1.
Also Read: World Organ Donation Day 2025: Theme, History, And Importance
The WHO also confirmed that current data does not indicate that this variant leads to more severe illness or deaths than the other currently active variants in circulation.
While the strain is said to be not a cause of concern, the symptoms may be unique from what we traditionally know COVID symptoms to be.
The WHO however, time and again has said that there is no increase in severity. It said, "While there are reported increases in cases and hospitalisations in some of the [South-east Asia Region] countries, which has the highest proportion of XFG, there are no reports to suggest that the associated disease severity is higher as compared to other circulating variants."
Dr Allen also seconded the opinion and said, "Based on the available information so far, there is no evidence to suggest that the XFG and XFG.3 variants cause more severe disease than previous variants, or that the vaccines in current use will be less effective against them.”
Other than these unique symptoms, the common COVID symptoms like change in smell or taste, shortness of breath and chest discomfort remain, however, it may be uncommon in vaccinated individuals.
XFG is growing rapidly compared to co-circulating variants globally. However, XFG exhibits only marginal additional immune evasion over [other varient] LP.8.1. While there are reported increases in cases and hospitalizations in some of the [South-east Asia Region] countries, which has the highest proportion of XFG, there are no reports to suggest that the associated disease severity is higher as compared to other circulating variants. The available evidence on XFG does not suggest additional public health risks relative to the other currently circulating Omicron descendant lineages," said WHO.
The WHO said that as per the current available data, the currently approved COVID-19 vaccines are expected to remain effective against symptomatic and severe diseases, including caused by the new strain.
However, Dr Kaywaan Khan, Harley Street GP and founder of Hannah London Clinic told Cosmopolitan UK that due to certain mutations in the spike protein in Stratus strain, it could evade antibodies "developed from prior infections or vaccinations".
While WHO noted that the risk of vaccine evasion is low, it also noted that more studies must be added to assess the risk of antibody escape.
Credits: Canva
Every year, on August 13, World Organ Donation Day is observed, globally, to spread awareness about the importance of organ donation and to make people aware about the misconceptions that surround organ donation.
This year's theme for World Organ Donation Day is 'Answering the Call'. This theme highlights the important function played by the professionals in the organ donation community. What it means is to encourage more to strengthen their dedication to save as many lives as possible through organ donation and transplantation.
The Pace Hospital notes that as of 2021, globally, 1,44,302 organ transplantations had occurred, of which, 26.44% were of deceased organ donation. India performed a total of 12,259 transplantation, contributing to 8% in global transplantations. In India, the most transplants that took place were for kidneys at 74.27%, liver at 23.33%, heart at 1.23%, lung at 1.08%, pancreas at 0.15%, and small intestine at 0.03%.
The overall number of deceased donors transplantation in India was 4.5%. While the deceased donors transplantation in India was reported 759 for kidney, 279 for liver and 99 for heart, the Indian Ministry of Health's estimated that it needs 175,000 kidneys, 50,000 livers, hearts, and lungs and 2,500 pancreas to meet the demand.
The Indian Ministry of Road and Transport and Highway's 2021 report notes that more than 1.5 lakh were reported as accident-related mortalities, however, only 552 deceased brain deaths organ transplantations took place in 2021. This is why it is more so important to raise awareness about organ donation to help those in requirement and reducing the number of patients on the waiting list.
It was in 1954, when the first successful organ transplant was performed. It was a kidney transplant by Dr Joseph Murray and his team at Peter Bent Brigham Hospital in Boston, Massachusetts.
The donor was Ronald Lee Herrick, who donated his organ to his twin brother Richard Herrick. Later in 1990, the doctor was honored with Nobel Prize in Physiology and Medicine for bringing advances in organ transplantation.
Th United Network for Organ Sharing (UNOS) highlights the timeline of the first donations and transplants performed of different organs.
In March 2024, a dedicated Delhi-based teacher, Meena Mehta was declared brain dead and her organs were donated to many, including her hands, shared her nephew Jawed Mehta. A 45-year-old Delhi-based painter had lost both his hands in a 2020 train accident, who received hand transplant. The hands were of Meena Mehta. After a 12-hour long surgery, the painter was able to paint again. Meena Mehta also donated her kidney, liver, and corneas, which has changed lives of three more people.
Credits: Wikimedia Commons
Nine-time Grand Slam champion Monica Seles is using her popularity and platform to shed light on a rare chronic neuromuscular condition that has changed her life. Myasthenia Gravis.
In an interview with Good Morning America on Tuesday, the former World No. 1 revealed for the first time that she was diagnosed three years ago with myasthenia gravis, or MG, an autoimmune disease that causes muscle weakness.
"It was 30 years ago that I came back to the [U.S.] Open ... It was like a reset, and this was one of the reasons I decided to go public with my myasthenia gravis," Seles said. "It’s been a huge reset not just in my professional life as a tennis player, but also in my personal life."
Seles, who last played professionally in 2003 and officially retired in 2008, said she hopes her story will help others who may be struggling with unexplained symptoms.
The 51-year-old said her training as a professional athlete helped her notice early changes in her body.
"I started experiencing these symptoms of extreme leg weakness, arm weakness, double vision. So I realized, ‘This is very unusual,’" she explained. "Once I was diagnosed, it was like a relief, but also it was a challenge."
Travel, once routine during her tennis career, has become more complicated. "Even coming here today, in the old days, traveling would be a no-brainer. Now I had to get packing tips. I had to learn a new way to live with MG," she said.
Seles admitted she had never heard of myasthenia gravis before her diagnosis. "I had no clue what it was. I had a hard time pronouncing it," she said with a smile.
She hopes that talking about her experience will encourage people to seek medical advice if they notice changes in their health.
"It’s been a very challenging time dealing with it," she added. "But knowing there’s hope out there and a great community has helped me tremendously."
Her message to others: "Advocate for yourself and know your symptoms."
Also Read: Tennis Player Monica Seles Opens Up About Her Myasthenia Gravis Diagnosis
According to the U.S. National Institute of Neurological Disorders and Stroke (NINDS), myasthenia gravis is a chronic neuromuscular disease that causes weakness in voluntary muscles, the muscles responsible for movements like walking, swallowing, breathing, and facial expressions.
MG occurs when the immune system mistakenly attacks healthy muscle receptors, disrupting the signals needed for muscle contraction. Johns Hopkins Medicine notes that the condition is not inherited or contagious and often develops later in life.
The disease can affect anyone, but it most commonly impacts women under 40 and men over 60. Symptoms may include:
Symptoms can vary widely between individuals. In rare situations, a myasthenic crisis may occur, affecting breathing muscles and requiring emergency medical care.
Because the symptoms of MG can resemble other health conditions, diagnosis involves a combination of physical and neurological exams, blood tests, and nerve stimulation studies.
There is currently no cure, but treatments can help manage symptoms and improve quality of life. These may include medications that enhance communication between nerves and muscles, immunosuppressive drugs, and in some cases, surgery to remove the thymus gland.
Temporary forms of MG can occur in newborns if a mother has the disease, but these cases usually resolve within two to three months.
While managing myasthenia gravis has brought challenges, Seles continues to find joy in life and in the sport she loves. She still follows tennis closely and is excited about the current generation of players.
"I wish I had a crystal ball," she said. "I love Coco Gauff, the electricity she brought to the U.S. Open. As a tennis fan, we just want great matches and the excitement of the fans."
By sharing her personal journey, Seles hopes to break the silence around MG and help others feel less alone. "When I got diagnosed, I wished I had heard someone talk about it. Now, I hope my story can be that for someone else."
© 2024 Bennett, Coleman & Company Limited